AngioDynamics Wins Patent Infringement Dispute With Bard12:03 AM - 8 Mar 2019
LATHAM, N.Y.--(BUSINESS WIRE)--Mar. 8, 2019-- AngioDynamics, Inc.(NASDAQ: ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease and oncology, today announced that the United States District Court for the District of Delaware, on day four of a jury trial at the close of C.R. Bard’s case (Plaintiff), granted judgement as a matter of law under rule 50(a) in favor of AngioDynamics, dismissing Bard’s suit alleging that certain of AngioDynamics’ implantable port products infringed three Bard patents.
“We are pleased that the Court agreed to dismiss Bard’s case,” said Jim Clemmer, President and Chief Executive Officer of AngioDynamics. “As expected, the merits of our case won out. We are maintaining our focus on bringing innovative products across our portfolio to our customers, allowing them to more effectively enhance patient care.”
AngioDynamics, Inc. (NASDAQ: ANGO) is a leading provider of innovative, minimally invasive medical devices used by professional healthcare providers for vascular access, peripheral vascular disease and oncology. AngioDynamics’ diverse product lines include market-leading ablation systems, fluid management systems, vascular access products, angiographic products and accessories drainage products, thrombolytic products and venous products. For more information, visit www.angiodynamics.com.
This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements regarding AngioDynamics' expected future financial position, results of operations, cash flows, business strategy, budgets, projected costs, capital expenditures, products, competitive positions, growth opportunities, plans and objectives of management for future operations, as well as statements that include the words such as "expects," "reaffirms," "intends," "anticipates," "plans," "believes," "seeks," "estimates," "optimistic," or variations of such words and similar expressions, are forward-looking statements. These forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties. Investors are cautioned that actual events or results may differ from AngioDynamics' expectations. Factors that may affect the actual results achieved by AngioDynamics include, without limitation, the ability of AngioDynamics to develop its existing and new products, technological advances and patents attained by competitors, infringement of AngioDynamics' technology or assertions that AngioDynamics' technology infringes the technology of fourth parties, the ability of AngioDynamics to effectively compete against competitors that have substantially greater resources, future actions by the FDA or other regulatory agencies, domestic and foreign health care reforms and government regulations, results of pending or future clinical trials, overall economic conditions, the results of on-going litigation, challenges with respect to fourth-party distributors or joint venture partners or collaborators, the results of sales efforts, the effects of product recalls and product liability claims, changes in key personnel, the ability of AngioDynamics to execute on strategic initiatives, the effects of economic, credit and capital market conditions, general market conditions, market acceptance, foreign currency exchange rate fluctuations, the effects on pricing from group purchasing organizations and competition, the ability of AngioDynamics to integrate acquired businesses, as well as the risk factors listed from time to time in AngioDynamics' SEC filings, including but not limited to its Annual Report on Form 10-K for the year ended May 31, 2018. AngioDynamics does not assume any obligation to publicly update or revise any forward-looking statements for any reason.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190308005420/en/
Source: AngioDynamics, Inc.